It remains halted. Earnings due on Nov. 2, a Thursday. In the past two weeks the Motley Fool stock touting outfit has been crowing about the short interest making the stock a buying opportunity. That and the medical reefer product.
The Nasdaq's third tier, the AMEX can be just as bad, and last but not least, the OTC, it seems, are financial venues that reward failure.